Compare Cytokinetics Inc (CYTK) vs Manulife Financial Corporation (MFC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Manulife Financial Corporation — how do they compare? Cytokinetics Inc trades at $76.67 (market cap $10.78B), while Manulife Financial Corporation trades at $43.84 (market cap $73.19B). The key difference: Manulife Financial Corporation is far larger — about 6.8× Cytokinetics Inc's market cap, and Manulife Financial Corporation pays a 3.08% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals.
| CYTK | MFC | |
|---|---|---|
Market Cap | $10.78B | $73.19B |
Sector | Technology | Financials |
52-Week High | $87.26 | $44.77 |
52-Week Low | $34.31 | $30.06 |
Enterprise Value | $10.88B | $68.35B |
Dividend Yield | — | 3.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cytokinetics (CYTK) trades at $76.76, down 5.67% today, with a bearish technical signal and negative profitability metrics. Recent Q2 2026 earnings beat EPS estimates but missed on revenue, while the company's drug Myqorzo shows strong commercial uptake and regulatory approvals in the UK. Cash flow remains negative from operations, offset by financing activities.
The outlook is mixed: strong analyst buy ratings (97%) and a $111.14 price target suggest upside, but high cash burn, competitive pressures, and lack of profitability pose significant risks. Investment appeal hinges on successful drug commercialization and path to profitability.
Manulife Financial (MFC) trades at $44.32, down 0.58% with a bullish technical outlook supported by moving averages. The company reported strong Q2 2026 results with double-digit growth in Asia and insurance sales, beating EPS expectations. Revenue reached $53.01B in 2025 with net income of $5.78B, though profit margins have moderated from 2022 peaks. Analysts maintain a Moderate Buy consensus with 57% buy ratings.
MFC presents a positive investment case with solid earnings growth, expanding Asian operations, and consistent dividend payments. However, premium valuation metrics and moderating profit margins warrant caution. The stock faces risks from wealth management outflows and competitive pressures in core markets, requiring careful monitoring of Q3 earnings performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Manulife Financial Corporation
Manulife provides life insurance and wealth management products and services to individuals and group customers in Canada, the United States, and Asia. Manulife is one of Canada's Big Three Life Insurance companies (the other two are Sun Life and Great West Life). As of Dec. 31, 2021, Manulife reported assets under management or administration of about CAD $1.4 trillion.
Read more on MFC →
